Eton Pharmaceuticals has submitted a Prior Approval Supplement (PAS) to the FDA for its KHINDIVI oral solution, seeking to expand its label to include pediatric patients under five years old. This move, if approved, would significantly broaden the product's addressable market and accelerate adoption, as the largest unmet need for an FDA-approved oral liquid hydrocortisone is in this younger age group.
Eton Pharmaceuticals has filed a Prior Approval Supplement (PAS) with the FDA to expand the label for its KHINDIVI oral solution to include pediatric patients under five years of age. This is a significant development because KHINDIVI is currently approved only for patients aged five and above, and the company identifies the largest unmet need for an FDA-approved oral liquid hydrocortisone in the younger demographic. If approved, which Eton anticipates in the first half of 2027, this expansion would drastically increase the product's addressable market and is expected to accelerate its adoption. For traders, this represents a long-term growth opportunity for ETON, as it targets a critical gap in the treatment of pediatric adrenal insufficiency, potentially leading to increased revenue and market share.